Evaluation of the expression of necroptosis pathway mediators and its association with tumor characteristics in functional and non-functional pituitary adenomas.
Functional pituitary adenomas
Necroptosis
Non-functional pituitary adenomas
Pituitary adenoma
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
04 Jan 2022
04 Jan 2022
Historique:
received:
27
08
2021
accepted:
15
12
2021
entrez:
5
1
2022
pubmed:
6
1
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Pituitary adenomas impose a burden of morbidity on patients and characterizing the molecular mechanisms underlying its pathogenesis received remarkable attention. Despite the appealing role of necroptosis as an alternative cell death pathway in cancer pathogenesis, its relevance to pituitary adenoma pathogenesis has yet to be determined that is perused in the current study. The total number of 109 specimens including pituitary adenomas and cadaveric healthy pituitary tissues were enrolled in the current study. Tumor and healthy pituitary tissues were subjected to RNA extraction and gene analysis using Real-Time PCR. The expression levels of necroptosis markers (RIP1K, RIP3K and, MLKL) and their association with the patient's demographic features were evaluated, also the protein level of MLKL was assessed using immunohistochemistry in tissues. Based on our data, the remarkable reduction in RIP3K and MLKL expression were detected in nonfunctional and GH-secreting pituitary tumors compared to pituitary normal tissues. Invasive tumors revealed lower expression of RIP3K and MLKL compared to non-invasive tumors, also the attenuated level of MLKL was associated with the tumor size in invasive NFPA. The simultaneous down-regulation of MLKL protein in pituitary adenoma tissues was observed which was in line with its gene expression. While, RIP1K over-expressed significantly in both types of pituitary tumors which showed no significant correlation with patient's age, gender and tumor size in GHPPA and NFPA group. Notably, MLKL and RIP3K gene expression was significantly correlated in the GHPPA group. According to our data, the reduced expression of necroptosis mediators (RIP3K, MLKL) in pituitary adenoma reinforces the hypothesis that the necroptosis pathway can be effective in regulating the proliferation and growth of pituitary tumor cells and tumor recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
Pituitary adenomas impose a burden of morbidity on patients and characterizing the molecular mechanisms underlying its pathogenesis received remarkable attention. Despite the appealing role of necroptosis as an alternative cell death pathway in cancer pathogenesis, its relevance to pituitary adenoma pathogenesis has yet to be determined that is perused in the current study.
METHODS
METHODS
The total number of 109 specimens including pituitary adenomas and cadaveric healthy pituitary tissues were enrolled in the current study. Tumor and healthy pituitary tissues were subjected to RNA extraction and gene analysis using Real-Time PCR. The expression levels of necroptosis markers (RIP1K, RIP3K and, MLKL) and their association with the patient's demographic features were evaluated, also the protein level of MLKL was assessed using immunohistochemistry in tissues.
RESULTS
RESULTS
Based on our data, the remarkable reduction in RIP3K and MLKL expression were detected in nonfunctional and GH-secreting pituitary tumors compared to pituitary normal tissues. Invasive tumors revealed lower expression of RIP3K and MLKL compared to non-invasive tumors, also the attenuated level of MLKL was associated with the tumor size in invasive NFPA. The simultaneous down-regulation of MLKL protein in pituitary adenoma tissues was observed which was in line with its gene expression. While, RIP1K over-expressed significantly in both types of pituitary tumors which showed no significant correlation with patient's age, gender and tumor size in GHPPA and NFPA group. Notably, MLKL and RIP3K gene expression was significantly correlated in the GHPPA group.
CONCLUSIONS
CONCLUSIONS
According to our data, the reduced expression of necroptosis mediators (RIP3K, MLKL) in pituitary adenoma reinforces the hypothesis that the necroptosis pathway can be effective in regulating the proliferation and growth of pituitary tumor cells and tumor recurrence.
Identifiants
pubmed: 34983494
doi: 10.1186/s12902-021-00919-y
pii: 10.1186/s12902-021-00919-y
pmc: PMC8725329
doi:
Substances chimiques
MLKL protein, human
EC 2.7.-
Protein Kinases
EC 2.7.-
RIPK1 protein, human
EC 2.7.11.1
RIPK3 protein, human
EC 2.7.11.1
Receptor-Interacting Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1Informations de copyright
© 2021. The Author(s).
Références
Radiat Prot Dosimetry. 2015 Sep;166(1-4):170-3
pubmed: 25899608
Tumour Biol. 2016 Feb;37(2):2405-14
pubmed: 26383518
Semin Cell Dev Biol. 2015 Mar;39:56-62
pubmed: 25683283
Cancer. 2004 Aug 1;101(3):613-9
pubmed: 15274075
Pituitary. 2014 Apr;17(2):157-62
pubmed: 23512699
Aging Cell. 2018 Aug;17(4):e12770
pubmed: 29696779
Acta Pharmacol Sin. 2017 Nov;38(11):1543-1553
pubmed: 28816233
Carcinogenesis. 2013 Sep;34(9):2119-28
pubmed: 23633517
Nanoscale. 2015 Jun 28;7(24):10634-40
pubmed: 26022234
Tumour Biol. 2016 Jul;37(7):8849-56
pubmed: 26749282
Tumour Biol. 2013 Feb;34(1):241-9
pubmed: 23055198
Histol Histopathol. 2008 Oct;23(10):1259-68
pubmed: 18712678
Tumour Biol. 2016 Apr;37(4):4479-91
pubmed: 26496737
BMC Endocr Disord. 2021 Mar 18;21(1):50
pubmed: 33736633
Cell Death Differ. 2017 Jul;24(7):1184-1195
pubmed: 28498367
Mediators Inflamm. 2015;2015:128076
pubmed: 26491219
Curr Pain Headache Rep. 2018 Jun 15;22(8):55
pubmed: 29904889
Am J Health Syst Pharm. 2018 Jul 1;75(13):945-952
pubmed: 29759975
Cancer Res. 2009 Apr 1;69(7):2809-16
pubmed: 19339267
J Neurooncol. 2014 May;117(3):459-68
pubmed: 24584748
Endocrinol Metab Clin North Am. 2015 Mar;44(1):79-87
pubmed: 25732644
Pituitary. 2003;6(3):127-33
pubmed: 14971737
BMC Cancer. 2013 Dec 06;13:580
pubmed: 24314238
Cancer Res. 2015 Apr 15;75(8):1736-48
pubmed: 25724678
Lipids Health Dis. 2019 Jul 9;18(1):152
pubmed: 31288808
Oxid Med Cell Longev. 2018 Jan 31;2018:3537471
pubmed: 29636841
Tumori. 2003 Jan-Feb;89(1):54-9
pubmed: 12729363
World Neurosurg. 2014 Mar-Apr;81(3-4):494-6
pubmed: 24215871
FEBS J. 2017 Sep;284(18):3050-3068
pubmed: 28715128
Cell Res. 2015 Jun;25(6):707-25
pubmed: 25952668
J Invest Dermatol. 2015 Aug;135(8):2021-2030
pubmed: 25748555
Neurosurgery. 2016 Dec;79(6):823-831
pubmed: 26692108
Neuroendocrinology. 2006;83(3-4):179-88
pubmed: 17047381